[go: up one dir, main page]

TNSN98124A1 - Compositions de sertraline solubilisee - Google Patents

Compositions de sertraline solubilisee

Info

Publication number
TNSN98124A1
TNSN98124A1 TNTNSN98124A TNSN98124A TNSN98124A1 TN SN98124 A1 TNSN98124 A1 TN SN98124A1 TN TNSN98124 A TNTNSN98124 A TN TNSN98124A TN SN98124 A TNSN98124 A TN SN98124A TN SN98124 A1 TNSN98124 A1 TN SN98124A1
Authority
TN
Tunisia
Prior art keywords
sertraline
compositions
solubilized
solubilized sertraline
sertraline compositions
Prior art date
Application number
TNTNSN98124A
Other languages
English (en)
Inventor
Thomas Friesen Dwayne
Max Herbig Scott
Mysore Shanker Ravi
Blair West James
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN98124(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN98124A1 publication Critical patent/TNSN98124A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION COMPRENANT DE DE LA SERTRALINE ET UN AGENT SOLUBILISANT, PERMETTANT D'ATTEINDRE UNE PLUS FORTE CONCENTRATION DE SERTRALINE DISSOUTE DANS UN ENVIRONNEMENT D'UTILISATION. ELLE CONCERNE EGALEMENT UN PROCEDE POUR ACCROITRE LA SOLUBILITE DE LA SERTRALINE ET UN PROCEDE DE PREPARATION D'UNE FORME POSOLOGIQUE DE SERTRALINE A SOLUBILITE ACCRUE. APPLICATION : UTILISATION POUR LE TRAITEMENT D'UNE MALADIE PSYCHIATRIQUE OU D'AUTRES MALADIES
TNTNSN98124A 1997-07-01 1998-06-30 Compositions de sertraline solubilisee TNSN98124A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
TNSN98124A1 true TNSN98124A1 (fr) 2005-03-15

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98124A TNSN98124A1 (fr) 1997-07-01 1998-06-30 Compositions de sertraline solubilisee

Country Status (34)

Country Link
EP (1) EP0999829A1 (fr)
JP (1) JP2000514100A (fr)
KR (1) KR100366373B1 (fr)
CN (1) CN1261794A (fr)
AP (1) AP1192A (fr)
AR (3) AR015917A1 (fr)
AU (1) AU742535B2 (fr)
BG (1) BG103918A (fr)
BR (1) BR9810739A (fr)
CA (1) CA2290974C (fr)
CO (1) CO4940495A1 (fr)
DZ (1) DZ2548A1 (fr)
EA (1) EA002481B1 (fr)
HN (1) HN1998000102A (fr)
HR (1) HRP980377A2 (fr)
HU (1) HUP0002236A3 (fr)
ID (1) ID23429A (fr)
IL (1) IL133076A (fr)
IS (1) IS5260A (fr)
MA (1) MA24587A1 (fr)
NO (1) NO996520L (fr)
OA (1) OA11243A (fr)
PA (1) PA8454301A1 (fr)
PE (1) PE97199A1 (fr)
PL (1) PL337804A1 (fr)
SK (1) SK181099A3 (fr)
TN (1) TNSN98124A1 (fr)
TR (1) TR199903297T2 (fr)
TW (1) TW550087B (fr)
UA (1) UA67741C2 (fr)
UY (1) UY25071A1 (fr)
WO (1) WO1999001120A1 (fr)
YU (1) YU68299A (fr)
ZA (1) ZA985708B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002017918A2 (fr) 2000-08-30 2002-03-07 Pfizer Products Inc. Formulations a liberation prolongee pour les secretagogues de l'hormone de croissance
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
KR101500020B1 (ko) * 2007-03-12 2015-03-06 디에스엠 아이피 어셋츠 비.브이. 미용 조성물
EP2520299A1 (fr) * 2009-12-29 2012-11-07 Kowa Co., Ltd. Composition pharmaceutique solide pour l'administration orale
EP2520300A4 (fr) * 2009-12-29 2013-05-08 Kowa Co Composition pharmaceutique pour administration orale
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736A (zh) * 2022-05-20 2022-08-12 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612B1 (fr) * 1989-08-30 1993-11-10 Pfizer Inc. Utilisation de la sertraline pour le traitement des dépendances aux produits chimiques
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
MA24587A1 (fr) 1998-12-31
UY25071A1 (es) 2000-12-29
OA11243A (en) 2003-07-24
UA67741C2 (uk) 2004-07-15
AR015917A1 (es) 2001-05-30
EP0999829A1 (fr) 2000-05-17
WO1999001120A1 (fr) 1999-01-14
PE97199A1 (es) 1999-10-05
IL133076A (en) 2003-12-10
HUP0002236A3 (en) 2003-12-29
EA199900962A1 (ru) 2000-08-28
CA2290974A1 (fr) 1999-01-14
AU742535B2 (en) 2002-01-03
PA8454301A1 (es) 2000-09-29
BG103918A (en) 2000-07-31
TR199903297T2 (xx) 2000-07-21
PL337804A1 (en) 2000-09-11
DZ2548A1 (fr) 2003-02-08
AR040280A2 (es) 2005-03-23
JP2000514100A (ja) 2000-10-24
YU68299A (sh) 2002-06-19
ZA985708B (en) 2000-01-10
IS5260A (is) 1999-11-19
CO4940495A1 (es) 2000-07-24
BR9810739A (pt) 2000-09-12
KR20010013365A (fr) 2001-02-26
HUP0002236A2 (hu) 2003-08-28
AR040279A2 (es) 2005-03-23
CA2290974C (fr) 2004-04-27
AP9801280A0 (en) 1998-06-30
TW550087B (en) 2003-09-01
SK181099A3 (en) 2000-07-11
NO996520L (no) 2000-02-29
HN1998000102A (es) 1999-01-08
IL133076A0 (en) 2001-03-19
NO996520D0 (no) 1999-12-28
EA002481B1 (ru) 2002-06-27
AP1192A (en) 2003-07-23
KR100366373B1 (ko) 2003-01-14
ID23429A (id) 2000-04-20
HRP980377A2 (en) 1999-04-30
AU7544898A (en) 1999-01-25
CN1261794A (zh) 2000-08-02

Similar Documents

Publication Publication Date Title
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99203A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00252A1 (fr) Compositions pharmaceutiques engendrant des concentrations accrues de medicaments
TNSN98025A1 (fr) Derives d'acide arylsulfonylhydroxamique, procede pour leur preparation et compositions les contenant.
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00071A1 (fr) Composition pharmaceutique comprenant un inhibiteur de cyp2d6 et un medicament a metabolisme catalyse par cyp2d6
TNSN99162A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN98022A1 (fr) DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
BE1002249A4 (fr) Compositions pharmaceutiques.
TNSN99055A1 (fr) Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01173A1 (fr) Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda.
TNSN98216A1 (fr) Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99133A1 (fr) Procede perfectionne pour la preparation de bases de schiff et produits ainsi obtenus